Nivolumab (Opdivo) for Stage IV Cancer
Also known as: Opdivo, BMS-936558
A cornerstone PD-1 inhibitor with extensive combination therapy data, particularly with ipilimumab for dual checkpoint blockade.
Mechanism of Action
Nivolumab binds PD-1 receptor with high affinity, blocking both PD-L1 and PD-L2 interactions. Unlike pembrolizumab (IgG4), nivolumab is a fully human IgG4 antibody. The dual checkpoint approach (nivolumab + ipilimumab) simultaneously blocks PD-1 and CTLA-4, providing complementary T cell activation signals.
General mechanism: Fully human anti-PD-1 monoclonal antibody. Restores anti-tumor T cell immunity by blocking PD-1/PD-L1 axis.
Current Evidence
CheckMate trials demonstrate efficacy across melanoma, renal cell carcinoma, hepatocellular carcinoma, and NSCLC. Nivolumab + ipilimumab combination shows superior response rates in melanoma and renal cancer compared to either agent alone, with long-term durable responses.
Clinical Status: FDA-approved for 15+ indications. Nivolumab + ipilimumab is standard first-line for advanced melanoma and renal cell carcinoma.
Safety Profile
Similar immune-related adverse event profile to pembrolizumab. Combination with ipilimumab increases toxicity rate to 40-60% but most events are manageable.
Key Research Questions
- What is the optimal sequencing of nivolumab combinations with targeted therapies?
- Can neoadjuvant nivolumab improve surgical outcomes in resectable disease?
- How does tumor microenvironment composition predict response to dual checkpoint blockade?